Payment overview · 2025
General Payments
$10,439.51
39 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Tahara, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · BRADFORD, PA · NPI 1902859069
Verified facts
What the public records show
CMS Open Payments records show Robert Tahara, MD received $10,439.51 in general payments during 2025 across 39 reported records.
AngioDynamics, Inc. accounted for 72.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $7,527.83 | 72.1% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $553.96 | 5.3% | 4 | 2025 |
| Infraredx, Inc. | Unresolved — no canonical attribution shown | $500.00 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$387.92 | 3.7% | 5 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $332.91 | 3.2% | 4 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $227.95 | 2.2% | 11 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $148.90 | 1.4% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $146.31 | 1.4% | 1 | 2025 |
| Canon Medical Systems USA, Inc. | Unresolved — no canonical attribution shown | $133.57 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $97.62 | 0.9% | 1 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $95.22 | 0.9% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $94.87 | 0.9% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $82.98 | 0.8% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $69.45 | 0.7% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.30 | 0.2% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $14.72 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $7,500.00 | 1 |
| Food and Beverage | $2,439.51 | 37 |
| Consulting Fee | $500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $7,527.83 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $553.96 | 4 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $167.45 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $165.49 | 2 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $165.46 | 1 | 2025 |
Source payment records
|
|||||
| Hemodialysis System Normalized: hemodialysis system |
Device | Nipro Medical Corporation | $148.90 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $146.31 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $146.31 | 1 | 2025 |
Source payment records
|
|||||
| Phi 100 Flex coil Normalized: phi 100 flex coil |
Device | Canon Medical Systems USA, Inc. | $133.57 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $106.16 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $95.22 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $84.37 | 1 | 2025 |
Source payment records
|
|||||
| Visions 035 Normalized: visions 035 |
Device | Philips North America LLC | $82.98 | 1 | 2025 |
Source payment records
|
|||||
| PRUITT F3 CAROTID SHUNT Normalized: pruitt f3 carotid shunt |
Device | LeMaitre Vascular, Inc. | $69.45 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $46.69 | 1 | 2025 |
Source payment records
|
|||||
| REBARTM Normalized: rebartm |
Device | Medtronic, Inc. | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xarelto | Rivaroxaban | 332 | 52 |
| Eliquis | Apixaban | 196 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 45 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,439.51 · 39 records | AngioDynamics, Inc. | ABRE, AURYON LASER SYSTEM 100-120 VAC, BioMimics 3D Vascular Stent System, ENDOCROSS Device, ESPRIT, Flexitouch Plus, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, Hemodialysis System, IN.PACT AV, Nimbl, PRUITT F3 CAROTID SHUNT, Phi 100 Flex coil, REBARTM, SURGICEL NU-KNIT, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VENASEAL, Venclose Maven Catheter, Venovo, Visions 035 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error